Edesa Biotech wins FDA IND clearance for Phase 2 vitiligo study

Edesa's anti-CXCL10 antibody EB06 can now enrol US patients, with topline data from the 80-person trial expected in Q4 2027.

The Biotech Times Editorial Team By The Biotech Times Editorial Team AI level 2 of 5
AI level 2 of 5: drafted by our AI editorial assistant from the company's announcement; fact-checked, edited and signed off by Mark Walker, Editorial Director. What the levels mean
A modern white medical ventilator with an attached corrugated tube sits on a clean white counter, plugged into an outlet, in a bright, sterile room with a large window.

Edesa Biotech has received FDA clearance for its Investigational New Drug application covering the Phase 2 evaluation of EB06 in moderate-to-severe nonsegmental vitiligo. The clearance allows the Toronto-listed clinical-stage company to expand recruitment from Canada into the United States, with the first American sites expected to begin enrolling patients in the first quarter of 2027. Topline data are anticipated in the fourth quarter of next year.

EB06 is a fully human monoclonal antibody that binds to CXCL10, a chemokine implicated in the autoimmune cascade that destroys melanocytes in vitiligo patients. By blocking CXCL10, the candidate is designed to interrupt trafficking of anti-melanocytic CD8+ T-cells to the skin and to prevent melanocyte apoptosis via the CXCR3B receptor. Edesa positions the mechanism as more targeted than broader immunomodulatory approaches, though as the company notes, safety and efficacy remain subject to clinical evaluation.

Trial design

The double-blind, placebo-controlled study will enrol up to 80 adults, randomised 1:1 to receive EB06 or placebo every two weeks through Week 22. The primary endpoint is the mean percentage change from baseline in the Facial Vitiligo Area Scoring Index at Week 28. Secondary measures include whole-body scoring benchmarks and assessments of pharmacokinetics and immunogenicity. EB06 has previously been evaluated in 65 subjects across three earlier clinical studies, where it demonstrated pharmacodynamic activity consistent with its proposed mechanism and was reported to be generally well tolerated.

Chief executive Par Nijhawan said: "FDA clearance of our IND represents an important regulatory and operational milestone for our vitiligo program. With recruitment already underway in Canada and U.S. enrollment expected to begin next quarter, we believe we are well positioned to complete the study and report topline results in the fourth quarter of next year."

Market context

Vitiligo affects an estimated 2% of the global population and, as Edesa notes, currently has no approved systemic drug therapy in the United States, making it an underserved indication with meaningful commercial headroom. That gap has attracted growing interest from mid-sized dermatology and immunology players. Incyte's ruxolitinib cream (Opzelura) received US approval for non-segmental vitiligo in 2022 as a topical JAK inhibitor, establishing the first approved treatment in the indication, but a systemic option remains absent. Several companies, including Pfizer and others pursuing JAK and TYK2 pathways, are active in this space, making the differentiated mechanism of CXCL10 inhibition strategically interesting if Phase 2 data prove out.

Edesa's pipeline extends beyond vitiligo: its daniluromer asset is described as Phase 3-ready for chronic allergic contact dermatitis, and paridiprubart is being evaluated for acute respiratory distress syndrome with backing from the Canadian government and a US government-funded platform study. For investors, the IND clearance is primarily a de-risking event rather than a data catalyst, but it meaningfully broadens the addressable recruitment pool and improves the likelihood of hitting the 2027 readout window on schedule. The shift to a subcutaneous formulation of EB06, flagged as a follow-on development priority, would further improve commercial appeal if the intravenous programme succeeds.

Sector

Topic

Geography